209 related articles for article (PubMed ID: 17549403)
1. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells.
Tsuchiya K; Hosoi H; Misawa-Furihata A; Houghton PJ; Sugimoto T
Int J Oncol; 2007 Jul; 31(1):41-7. PubMed ID: 17549403
[TBL] [Abstract][Full Text] [Related]
2. Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor.
Thulasi R; Dias P; Houghton PJ; Houghton JA
Cell Growth Differ; 1996 Apr; 7(4):531-41. PubMed ID: 9052994
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Hosoi H; Dilling MB; Shikata T; Liu LN; Shu L; Ashmun RA; Germain GS; Abraham RT; Houghton PJ
Cancer Res; 1999 Feb; 59(4):886-94. PubMed ID: 10029080
[TBL] [Abstract][Full Text] [Related]
5. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M
Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075
[TBL] [Abstract][Full Text] [Related]
6. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin.
Louro ID; McKie-Bell P; Gosnell H; Brindley BC; Bucy RP; Ruppert JM
Cell Growth Differ; 1999 Jul; 10(7):503-16. PubMed ID: 10437918
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Wnt/β-catenin signaling in rhabdomyosarcoma.
Annavarapu SR; Cialfi S; Dominici C; Kokai GK; Uccini S; Ceccarelli S; McDowell HP; Helliwell TR
Lab Invest; 2013 Oct; 93(10):1090-9. PubMed ID: 23999248
[TBL] [Abstract][Full Text] [Related]
8. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development.
Tonin PN; Scrable H; Shimada H; Cavenee WK
Cancer Res; 1991 Oct; 51(19):5100-6. PubMed ID: 1717137
[TBL] [Abstract][Full Text] [Related]
9. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues.
Kumar S; Perlman E; Harris CA; Raffeld M; Tsokos M
Mod Pathol; 2000 Sep; 13(9):988-93. PubMed ID: 11007039
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
[TBL] [Abstract][Full Text] [Related]
11. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
12. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
13. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
Kalebic T; Tsokos M; Helman LJ
Cancer Res; 1994 Nov; 54(21):5531-4. PubMed ID: 7923191
[TBL] [Abstract][Full Text] [Related]
14. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
15. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
[TBL] [Abstract][Full Text] [Related]
16. Studies on the mechanism of resistance to rapamycin in human cancer cells.
Hosoi H; Dilling MB; Liu LN; Danks MK; Shikata T; Sekulic A; Abraham RT; Lawrence JC; Houghton PJ
Mol Pharmacol; 1998 Nov; 54(5):815-24. PubMed ID: 9804616
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway.
Han B; Tong J; Zhu MJ; Ma C; Du M
Mol Reprod Dev; 2008 May; 75(5):810-7. PubMed ID: 18033679
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro.
Herrmann D; Seitz G; Warmann SW; Bonin M; Fuchs J; Armeanu-Ebinger S
J Immunother; 2010 Apr; 33(3):279-86. PubMed ID: 20445348
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
20. FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells.
Wachtel M; Rakic J; Okoniewski M; Bode P; Niggli F; Schäfer BW
Int J Cancer; 2014 Oct; 135(7):1543-52. PubMed ID: 24550147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]